Literature DB >> 11740958

Bimatoprost and its free acid are prostaglandin FP receptor agonists.

N A Sharif1, G W Williams, C R Kelly.   

Abstract

Bimatoprost (17-phenyl-prostaglandin F(2alpha) ethyl amide) has been reported not to exert its actions via prostaglandin receptors. Here, bimatoprost displaced [3H]prostaglandin F(2alpha) from FP receptors (K(i)=6310+/-1650 nM). Bimatoprost rapidly mobilized intracellular Ca(2+) ([Ca(2+)](i)) via cloned human FP receptors expressed in human embryonic kidney cells (EC(50)=2940+/-1663 nM) and via native FP receptors in 3T3 mouse fibroblasts (EC(50)=2200+/-670 nM). Furthermore, AL-8810 ((5Z, 13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid), an FP receptor antagonist, blocked the bimatoprost-induced [Ca(2+)](i) mobilization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740958     DOI: 10.1016/s0014-2999(01)01486-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Pharmacological characterization of prostanoid receptors mediating vasoconstriction in human umbilical vein.

Authors:  Federico Manuel Daray; Ana Itatí Minvielle; Soledad Puppo; Rodolfo Pedro Rothlin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

2.  Cellular basis for bimatoprost effects on human conventional outflow.

Authors:  W Daniel Stamer; David Piwnica; Thierry Jolas; Robert W Carling; Clive L Cornell; Hans Fliri; Jose Martos; Simon N Pettit; Jenny W Wang; David F Woodward
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

3.  Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.

Authors:  D F Woodward; A H Krauss; J W Wang; C E Protzman; A L Nieves; Y Liang; Y Donde; R M Burk; K Landsverk; C Struble
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

4.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

5.  Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.

Authors:  Michele Vetrugno; Nicola Cardascia; Francesco Cantatore; Carlo Sborgia
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

6.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

7.  A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.

Authors:  Gianluca Manni; Marco Centofanti; Mariacristina Parravano; Francesco Oddone; Massimo G Bucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

8.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

9.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 10.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.